Ernexa Therapeutics Inc
ernexatx.comWhat Do They Do?
Develops off-the-shelf engineered stem-cell treatments for patients with cancer and autoimmune diseases.
10-K for FY2025, filed Mar 13, 2026We are a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are induced pluripotent stem cell (“iPSC”)-derived mesenchymal…View ↗
Our lead product candidate ERNA-101 is allogenic IL-7 and IL-15-secreting iMSCs. ERNA-101 capitalizes on the intrinsic tumor-homing ability…View ↗
We are also investigating anti-inflammatory cytokine (e.g., IL-10)-secreting iMSCs in autoimmune disorders like rheumatoid arthritis, which…View ↗
How Do They Make Money?
A customer paid an upfront fee for an option to license technology and an initial payment for cell-line work. After Ernexa assigned the contract, Factor paid Ernexa a share of customization receipts and would pay a share if the customer exercised the option.
10-K for FY2025, filed Mar 13, 2026
$582K
-
10-K for FY2025, filed Mar 13, 2026
$582K ↗
Who Are Their Customers?
A customer contracted for an option to sublicense intellectual property and customized cell-line work; after Ernexa assigned the contract, Factor Limited paid Ernexa a share of customization receipts.
10-K for FY2025, filed Mar 13, 2026
Do Revenues Turn Into Profits?
No. It lost $44.5M in FY2024.
10-K for FY2025, filed Mar 13, 2026
−$15.7MView ↗
10-K for FY2025, filed Mar 13, 2026
−$44.5MView ↗
10-K for FY2025, filed Mar 13, 2026
−$16.2MView ↗
How Are They Changing?
-
Mar 20, 2026
Nasdaq found Ernexa out of compliance with the minimum bid-price rule
Ernexa planned to request a hearing and present a plan to regain compliance.
Sources
8-K, filed Mar 20, 2026
On March 18, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”, or “our”), received a written notice (the…View ↗
Shrinking. Revenue fell 90% in 4 years, from $5.8M in FY2020 to $582K in FY2024, about 44% a year.
From mRNA platform to iMSC therapies
The older report described a broad mRNA cell-engineering platform intended for development through strategic partnerships. The latest report focuses on synthetic stem-cell therapy candidates for cancer and autoimmune diseases, while still seeking partnerships.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Mar 13, 2026We are a preclinical-stage biopharmaceutical company committed to realizing the potential of mRNA cell engineering to provide patients with…View ↗
We are a preclinical-stage synthetic allogeneic iMSC therapy company. iMSCs are induced pluripotent stem cell (“iPSC”)-derived mesenchymal…View ↗
Our lead product candidate ERNA-101 is allogenic IL-7 and IL-15-secreting iMSCs. ERNA-101 capitalizes on the intrinsic tumor-homing ability…View ↗
We are also investigating anti-inflammatory cytokine (e.g., IL-10)-secreting iMSCs in autoimmune disorders like rheumatoid arthritis, which…View ↗
Additionally, to expand our developmental opportunities and raise non-dilutive capital, we are actively seeking strategic partnerships to…View ↗
Loading...
